[Evaluation of the clinical results of implantation the hydrophobic-hydrophilic intraocular lens ERIFLEX 877 FAB].
OBJECTIVE
To evaluate the properties of intraocular lens ERIFLEX 877 FAB, the manipulation during implantation and clinical outcomes after implantation of the new hydrophobic-hydrophilic intraocular lens in patients undergoing routine cataract surgery.


METHODS
The study included 30 patients (38 eyes), mean age 71 ± 8 years (range 53-89 years) with senile cataract. After phacoemulsification intraocular lens ERIFLEX 877 FAB was implanted. Patients were evaluated at 3 months after surgery. We assessed the uncorrected visual acuity (UCVA) and best corrected visual acuity (BCVA), refraction, keratometry and the incidence of posterior capsule opacification (PCO - Posterior capsule opacification). Individual patients and surgeons satisfaction was also documented including manipulation during surgery.


RESULTS
Three months after surgery, the mean UCVA was 0.7 ± 0.2 and BCVA was 0.97 ± 0.16. PCO value was 0.15 ± 0.09, that means minimal incidence of PCO. Good UCVA and a minimal incidence of PCO have resulted in a high degree satisfaction of patients.


CONCLUSIONS
The new hydrophobic-hydrophilic intraocular lens ERIFLEX 877 FAB could be easily implanted and after surgery shows a high degree of biocompatibility in patients undergoing routine cataract surgery.
A
A
Stepanov
N
N
Jirásková
J
J
Nekolová
J
J
Lackovič
J
J
Románek
P
P
Rozsíval
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D019654:Lens Implantation, Intraocular / Q000379:methods*; D007910:Lenses, Intraocular; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification / Q000379:methods*; D011474:Prosthesis Design; D014792:Visual Acuity